TABLE 3

Source of isolates and method of susceptibility testing

CollectionNo. of isolatesSourceaSpecimen typeDatesSusceptibility testing methodsSequencing
Derivation set collections (n = 501)88Brighton (all wards)Blood1999–2007Automated broth dilution (Vitek), clinical laboratoryPreviously sequenced
90Brighton carriage (ITU)Nasal swab2010–2011Disc diffusion, clinical laboratoryPreviously sequenced
323Oxford (all wards)Blood2008–2011Disc diffusion, clinical laboratoryPreviously sequenced
Validation set collections (n = 491)102Oxford carriage (ITU)Nasal swab2009Disc diffusion and automated broth dilution (BD Phoenix)Previously sequenced
100Oxford carriage (community)Nasal swab2009Disc diffusion and automated broth dilution (BD Phoenix)Previously sequenced
165Brighton (all wards)Blood2011–2012Disc diffusion and automated broth dilution (BD Phoenix)Sequenced de novo, susceptibility testing performed from same subculture as sequencing
124Oxford (all wards)Blood2011–2012Disc diffusion and automated broth dilution (BD Phoenix)Sequenced de novo, susceptibility testing performed from same subculture as sequencing
  • a Brighton, Brighton and Sussex University Hospitals NHS Trust; Oxford, Oxford Radcliffe Hospitals NHS Trust; ITU, intensive therapy unit.